Thermo Fisher Scientific (TMO) Accumulated Expenses (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Accumulated Expenses for 18 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 11.59% year-over-year to $1.7 billion; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 11.59% YoY), and the FY2025 full-year result was $2.0 billion, changed 0.35% from the prior year.
• Accumulated Expenses rose to $1.7 billion in Q2 2026 per TMO's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $2.1 billion in Q4 2022 and bottomed at $1.3 billion in Q2 2023.
• Historically, Accumulated Expenses has averaged $1.6 billion across 5 years, with a median of $1.6 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses decreased 23.93% in 2023, then rose 24.86% in 2024.
• Over 5 years, Accumulated Expenses stood at $2.1 billion in 2022, then slipped by 23.82% to $1.6 billion in 2023, then grew by 24.56% to $2.0 billion in 2024, then increased by 0.35% to $2.0 billion in 2025, then decreased by 15.09% to $1.7 billion in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.7 billion, $1.6 billion, and $2.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.